Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has entered into active pharmaceutical ingredient (API) supply and joint development agreements with the US-based Cutis Pharma to advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.

This partnership has significant strategic benefits for both the entities. Dr Reddy’s breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organisations and will be a significant catalyst in its plans to fast-track the development of three of its programs towards new drug application (NDA) filings.

Cutis Pharma is a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, while Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.